Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDX-7108
- Development stage
- Phase 2
- Lead developer
- Nestlé Health Science
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
CDX-7108 is an **orally-administered, engineered lipase variant** being developed to treat **exocrine pancreatic insufficiency (EPI)**, a condition often resulting from diseases such as pancreatitis, pancreatic cancer, Crohn’s disease, celiac disease, and cystic fibrosis. CDX-7108 is specifically designed to address the limitations of traditional pancreatic enzyme replacement therapy (PERT) by exhibiting **enhanced stability in acidic gastric environments** and **resistance to proteolytic degradation in the upper intestine**. The drug aims to improve the digestion and absorption of fats. Interim Phase 1 trial data showed improved lipid absorption in EPI patients without notable safety issues. Clinical development is led through a partnership between Codexis and Nestlé Health Science, with Aimmune Therapeutics also mentioned as a co-developer or subsidiary involved[1][2][3][4][5][6][9][10].
- Other names
- New Lipase NHS7108
02
Targets
GehA (Triacylglycerol lipase GehA)
Beyond the preview
Go deeper on CDX-7108.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDX-7108.